Is Asarfi Hospital overvalued or undervalued?

As of 14 November 2025, Asarfi Hospital's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as overvalued. Key ratios include a PE ratio of 31.38, an EV to EBITDA of 16.34, and a PEG ratio of 0.20, which suggests growth potential relative to its valuation.
In comparison to peers, Apollo Hospitals has a significantly higher PE ratio of 63.77 and an EV to EBITDA of 33.53, while Max Healthcare is marked as very expensive with a PE of 89.07. Despite the recent strong stock performance, with a year-to-date return of 75.1% compared to the Sensex's 8.22%, the elevated valuation metrics indicate that Asarfi Hospital may not present an attractive investment opportunity at current levels.